AMAG Pharmaceutical’s HSDD drug Vyleesi, has been approved by the FDA. But analysts warn it must build the market in women who may not be aware they have a condition if it is to fare better than Sprout’s Addyi.
The US Food and Drug Administration has approved AMAG Pharmaceuticals Inc.’s Vyleesi (bremelanotide injection), a melanocortin receptor agonist, to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.
The Vyleesi autoinjector is the first treatment for this patient population that can be self-administered as needed in anticipation of...
The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.
Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.
Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.
